Skip to main content
OpenTrials

Clinical trial condition

Parkinson Disease 4, Autosomal Dominant Lewy Body

Explore clinical trials studying Parkinson Disease 4, Autosomal Dominant Lewy Body. Study availability and eligibility vary by location and protocol.

226 public trials 33 recruiting studies
Refine in advanced search Browse all conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body trial results

Completed

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

NCT05064059

Conditions
Colonic Diseases, Colorectal Cancer, Colorectal Neoplasms, +10 more
Locations
  • Georgetown University Hospital ( Site 1148) Washington D.C., District of Columbia, United States
  • Sibley Memorial Hospital ( Site 1143) Washington D.C., District of Columbia, United States
  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 1118) Marietta, Georgia, United States
  • Norton Cancer Institute ( Site 1139) Louisville, Kentucky, United States
View all 152 locations
View Trial Details
Completed

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

NCT03260894

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +15 more
Locations
  • Pinnacle Oncology Hematology Scottsdale, Arizona, United States
  • Scottsdale Healthcare Scottsdale, Arizona, United States
  • Arizona Oncology Associates PC- HOPE Tucson, Arizona, United States
  • Cedars-Sinai Medical Center Los Angeles, California, United States
View all 140 locations
View Trial Details
Completed

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

NCT04246177

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations
  • Arizona Oncology Associates PC- HOPE ( Site 0770) Tucson, Arizona, United States
  • Scripps Clinic Torrey Pines ( Site 0714) La Jolla, California, United States
  • USC Norris Comprehensive Cancer Center ( Site 0717) Los Angeles, California, United States
  • UCLA Hematology/Oncology - Santa Monica ( Site 0720) Los Angeles, California, United States
View all 205 locations
View Trial Details
Completed

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

NCT03797326

Conditions
Adnexal Diseases, Advanced Solid Tumors, Astrocytoma, +49 more
Locations
  • City of Hope ( Site 0002) Duarte, California, United States
  • Cedars Sinai Medical Center ( Site 0003) Los Angeles, California, United States
  • University of California Davis Comprehensive Cancer Center ( Site 0005) Sacramento, California, United States
  • University of Colorado, Anschutz Cancer Pavilion ( Site 0007) Aurora, Colorado, United States
View all 88 locations
View Trial Details
Completed

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

NCT03740165

Conditions
Abdominal Neoplasms, Adnexal Diseases, Digestive System Diseases, +22 more
Locations
  • University of Alabama at Birmingham (UAB) ( Site 0036) Birmingham, Alabama, United States
  • University of Arizona Cancer Center ( Site 0074) Tucson, Arizona, United States
  • Disney Family Cancer Center ( Site 0042) Burbank, California, United States
  • Kaiser Permanente Oncology Clinical Trial -Oakland ( Site 0077) Oakland, California, United States
View all 227 locations
View Trial Details
Completed

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

NCT04191096

Conditions
Metastatic Hormone-sensitive Prostate Cancer, Parkinson Disease 4, Autosomal Dominant Lewy Body
Locations
  • Alaska Clinical Research Center ( Site 0274) Anchorage, Alaska, United States
  • Providence Alaska Medical Center ( Site 0276) Anchorage, Alaska, United States
  • City of Hope Medical Center ( Site 0217) Duarte, California, United States
  • UCLA Hematology/Oncology - Santa Monica ( Site 0241) Los Angeles, California, United States
View all 234 locations
View Trial Details
Completed

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

NCT04662710

Conditions
Advanced/Metastatic Gastroesophageal Adenocarcinoma, Parkinson Disease 4, Autosomal Dominant Lewy Body
Locations
  • UCLA Hematology/Oncology - Santa Monica ( Site 0003) Los Angeles, California, United States
  • Georgetown University Medical Center ( Site 0009) Washington D.C., District of Columbia, United States
  • James Graham Brown Cancer Center ( Site 0017) Louisville, Kentucky, United States
  • Johns Hopkins University ( Site 0052) Baltimore, Maryland, United States
View all 177 locations
View Trial Details
Completed

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

NCT03867084

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +10 more
Locations
  • Banner MD Anderson Cancer Center ( Site 0026) Gilbert, Arizona, United States
  • The University of Arizona Cancer Center - North Campus ( Site 0039) Tucson, Arizona, United States
  • City of Hope Medical Center ( Site 0027) Duarte, California, United States
  • Smilow Cancer Hospital at Yale New Haven ( Site 0042) New Haven, Connecticut, United States
View all 249 locations
View Trial Details
Completed

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study

NCT04924062

Conditions
Adenocarcinoma, Bile Duct Diseases, Bile Duct Neoplasms, +14 more
Locations
  • Anhui Provincial Hospital ( Site 0140) Hefei, Anhui, China
  • Beijing Cancer Hospital ( Site 0138) Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital ( Site 0150) Beijing, Beijing Municipality, China
  • First Affiliated Hospital of The Third Military Medical University ( Site 0130) Chongqing, Chongqing Municipality, China
View all 22 locations
View Trial Details
Completed

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)

NCT04003636

Conditions
Adenocarcinoma, Bile Duct Diseases, Bile Duct Neoplasms, +14 more
Locations
  • University of Alabama at Birmingham Comprehensive Cancer Ctr ( Site 0016) Birmingham, Alabama, United States
  • University of California San Diego Moores Cancer Center ( Site 0008) La Jolla, California, United States
  • UCLA Hematology/Oncology - Santa Monica ( Site 0014) Los Angeles, California, United States
  • University of California - San Francisco ( Site 0030) San Francisco, California, United States
View all 185 locations
View Trial Details

Related conditions